TB-500Mobility and soft-tissue recovery — without the gray-market gamble.
A seven-amino-acid fragment of thymosin beta-4 studied for wound healing and soft-tissue repair.
TB-500 is what people reach for when tendons, ligaments, and mobility keep stalling. An FDA advisory committee recommended it for compounding in July 2026. Join the waitlist for first access when pharmacy-sourced TB-500 can be evaluated through AlphaMD.
By joining, you opt in to launch and marketing email about TB-500 from AlphaMD. You can unsubscribe at any time.
- U.S. compounding pharmacies only
- Discreet shipping
- 100% confidential
Why TB-500 Gets Attention
A compact fragment built for repair signaling.
TB-500 is a synthetic peptide seven amino acids long (Ac-LKKTETQ), lifted from positions 17–23 of thymosin beta-4 — a naturally occurring 43-amino-acid protein that helps govern how cells build and dismantle their internal scaffolding. The fragment was isolated because it appeared to carry actin-binding activity in a far smaller package.
That relationship matters for expectations. Full-length thymosin beta-4 has human clinical work in areas like dry eye and wound care. TB-500 is a shorter, separate molecule with its own animal data — especially dermal wound repair in aged and diabetic mice, where healing normally fails. Sellers often blur the two; this page does not.
In July 2026 an FDA advisory committee recommended TB-500 for the compounding bulk-substances list, 8 to 6 with one abstention. Reviewers found no clinical study administering TB-500 itself to a human. The waitlist is how you get first access when a U.S. pharmacy can lawfully produce and test the fragment you actually asked for.
Where TB-500 Stands Today
- Recommended for compoundingAdvisory vote 8–6 (1 abstention), July 23, 2026
- FDA scientists advised against itAgency staff recommended no; the advisory committee voted yes 8–6
- No human studies yetFDA found no clinical trials administering TB-500 to people
- Banned in tested sportProhibited by WADA at all times; also on the NCAA banned list
- Not an FDA-approved drugNo approved indication, no approved dosing label
- Prescription-only at launchProvider evaluation and intake required — no direct purchase
Claims online often borrow thymosin beta-4 results. Evidence labels below stay with the fragment itself. Final compounding still needs FDA rulemaking.
What You May Get From TB-500
The recovery upsides people want — with a clear label when a finding belongs to TB-500 versus full-length thymosin beta-4.
Dermal wound closure
The best-documented result for the fragment itself. LKKTETQ accelerated wound repair in aged and diabetic mice — models where healing is normally impaired.
Animal dataTendon and ligament repair
The reason most people ask. The rationale rests on actin regulation and cell migration into damaged tissue, supported so far in animal soft-tissue work.
Animal dataNew blood vessel growth
Thymosin beta-4 promotes angiogenesis and the fragment is proposed to share it — promising for tissue delivery, still unmeasured at typical human-use doses.
Lab dataMuscle and cardiac remodeling
Most of this work used full-length thymosin beta-4 in injury models. A hypothesis for the fragment, not a TB-500 human finding.
Animal dataLower inflammatory signaling
Reduced inflammatory markers across several animal injury models — consistently reported in preclinical work, not yet quantified in people.
Animal dataWho TB-500 May Be A Fit For
A provider makes this call with you after reviewing your history and labs.
- Recovering from a soft-tissue injury — a tendon, ligament, or muscle that has stalled short of full function.
- Training hard past 35 and accumulating overuse damage faster than rest alone clears it.
- Cleared post-surgically to heal — with your surgeon's sign-off before anything new is added.
- Not competing under an anti-doping code, because for tested athletes this one is disqualifying.
- Already an AlphaMD member who would rather add recovery support to an existing plan than open a second file elsewhere.
Who Should Skip It
Practical fit filters — a provider will decline when these apply.
- You compete in a tested sport. TB-500 is prohibited by WADA at all times and appears on the NCAA banned list. Strict liability means intent will not matter.
- You have an active or recent cancer diagnosis. Encouraging cells to migrate and blood vessels to grow is how this peptide is meant to help a wound. Effects near a tumor are unstudied.
- You are chasing pain relief alone. Feeling better and being structurally healed are different. Pair any recovery peptide with a real return-to-load plan.
- You're pregnant, nursing, or trying to conceive. No reproductive or developmental safety data exists.
- You're under 18, or you are unwilling to complete intake and follow-up.
What To Know About Risks
TB-500 has no established human side-effect profile, and FDA reviewers also judged the animal toxicology package thin. Here is the practical picture.
No human safety data yet
No clinical studies, no side-effect list, no dose-response curve for TB-500 itself. "Well tolerated" claims usually refer to thymosin beta-4 or forums.
Thin animal toxicology
FDA reviewers concluded the nonclinical package did not fully support the proposed use — another reason provider oversight matters at launch.
Immunogenicity and aggregation
Peptides can clump during synthesis and storage, and aggregates are more likely to provoke an immune response. Impurity characterization remains incomplete.
Unknown long-term tissue effects
A molecule meant to tell cells to migrate and rebuild has not been studied for months-long human use either way.
Injection complications
Pain, bruising, bleeding, infection, and abscess formation are risks of the needle itself.
Counterfeit and mislabeled product
TB-500 is heavily counterfeited, sometimes swapped with thymosin beta-4 — or with nothing. Pharmacy identity testing is the point of waiting.
Pharmacy-Sourced Beats Gray-Market Guesswork
TB-500 moves in huge volume online, often labeled "research only" and frequently confused with thymosin beta-4. Independent testing of gray-market vials keeps finding the same failures.
Gray-market vials
- Peptide content well under — or over — what the label claims
- Bacterial endotoxin from non-sterile production — a fever and sepsis risk you inject directly
- Residual synthesis solvents, heavy metals, and truncated peptide fragments
- Certificates of analysis that are copied, expired, or for an entirely different lot
- No prescriber, no recall path, and no one accountable if you're harmed
A U.S. compounding pharmacy
- State-licensed, FDA-inspected facility working from a real prescription
- Sterile compounding standards for anything injected, with documented process controls
- Third-party potency, sterility, and endotoxin testing tied to your specific lot
- A provider who sets your dose, reviews your labs, and owns follow-up
- Traceability — if a lot is bad, it can be found, pulled, and reported
When TB-500 launches with AlphaMD, members get a pharmacy that can prove which molecule is in the vial — after a provider evaluation.
Educational Resources
Deeper reading on what TB-500 is, how it differs from thymosin beta-4, and why sourcing decides most of the risk.
TB-500 benefits, risks, and side effects: what you need to know
The long-form deep dive: where the fragment came from, why thymosin beta-4 research gets misattributed, and what the FDA concluded.
The FDA compounding votes on BPC-157, TB-500, KPV and MOTs-c
What the July 2026 advisory committee decided and what still has to happen before compounding opens.
The peptide quality crisis nobody in the optimization space wants to admit
What third-party testing keeps finding in gray-market vials — and why counterfeit risk is highest for the loudest reputations.
Frequently Asked Questions
Still deciding? Message the team — you don't need to be a member to ask.
Ask a QuestionFirst access when pharmacy-compounded TB-500 can be offered through AlphaMD — provider evaluation, intake, and product from a U.S. compounding pharmacy that can prove identity and lot-level testing.
In July 2026 an FDA advisory committee recommended TB-500 for the 503A bulk-substances list. Final rulemaking still has to finish. Once a pharmacy AlphaMD trusts can lawfully produce and test it, the waitlist gets the email that week.
Not yet. Nothing on this page is for sale. If a clinic is offering TB-500 today, ask which licensed U.S. pharmacy compounded it and for lot-specific testing.
No. Thymosin beta-4 is a 43-amino-acid protein with human clinical work behind it. TB-500 is a seven-amino-acid fragment. It may share some activity, but human results from the full protein do not automatically transfer. Sellers blur the two constantly.
For the fragment specifically, not yet. FDA found no clinical study administering TB-500 to people. The animal wound-healing work is real research; it is not a human outcome.
Skip it. TB-500 is prohibited by WADA at all times and appears on the NCAA banned list. It will not be prescribed to a tested athlete through AlphaMD.
Not necessarily. Reduced pain is not the same as structural repair. Tendon remodeling takes months — imaging and a graded return-to-load plan answer this question better than a peptide alone.
No interaction is known. Raising it at your next visit keeps testosterone, labs, and anything new in the same chart.
Pricing is not set until a supplier is locked. When it is, it will be published the same way TRT pricing is: one clear number, per month.
Explore Other Peptides
Five more on the same July 2026 compounding slate — join each waitlist for first access when they launch.
Get First Access to TB-500
Join the waitlist for pharmacy-sourced TB-500 through AlphaMD — provider evaluation, identity-tested product, discreet shipping. Already a member? Bring peptides up at your next visit or book a consult to get intake done early.
By joining, you opt in to launch and marketing email about TB-500 from AlphaMD. You can unsubscribe at any time.
No insurance needed · Cancel anytime · 100% confidential
Legal Disclaimer
TB-500 is not an FDA-approved drug and is not currently available for sale or prescription through AlphaMD. Nothing on this page is an offer to sell, and nothing here is medical advice. Statements about potential benefits describe published preclinical laboratory and animal research and are not claims about outcomes for any individual. Peptide therapy, if and when offered, will require a consultation with a licensed medical professional, a completed medical intake, and appropriate laboratory testing; it is not appropriate for everyone. TB-500 is prohibited by the World Anti-Doping Agency at all times and appears on the NCAA list of banned substances.
Medical services are provided by independent, licensed providers through AlphaMD's affiliated professional practices. AlphaMD provides administrative and technology services and does not practice medicine.